Clinical trial · Interventional
Molecular Markers in Cancers and Precancers (MOCA)
Molecular Markers in Cancers and Precancers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): No enrollment
Summary
Brief summary (as posted)
In oncology, the search for genetic alterations or infectious agents in tumour tissues has become a major medical challenge for diagnosis, prognosis, prediction of response to treatment and in particular to targeted therapies, or for the biological monitoring of the disease. Over the last ten years, the development of new molecular biology tools based on high-throughput technologies has enabled us to revisit our conceptions of the development and natural history of cancers. The use of these tools has also allowed the dismemberment of numerous cancerous pathologies according to their molecular etiologies and oncogenetic histories. These new molecular biology tools have thus contributed to the emergence of so-called personalised or precision medicine.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Healthy | — | UNRESOLVED | — |
| Precancerous Lesion | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Molecular biology | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- intervention
- interventionNames
- Diagnostic Test: Molecular biology
Primary outcomes (4)
- measure
- Identification and prevalence of somatic mutations in precancers and cancers
- timeFrame
- 5 years
- description
- Somatic mutations will be identified from precancer and cancer tissues from different localisations and from circulating DNA by NGS.
- measure
- Identification and prevalence epigenetic modifications in precancers and cancers
- timeFrame
- 5 years
- description
- DNA methylation patterns will be identified from precancer and cancer tissues from different localisations and from circulating DNA by NGS or methylation specific PCR.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male and female patients with or without a precancerous lesion or cancer * Patients covered by a social security plan * Patients who have given their consent Exclusion Criteria: * Patient in emergency situation * Contraindication to tissue, cell, blood or other biological fluid collection * Subject unlikely to cooperate with the study and/or poor cooperation anticipated by the investigator * Legal incapacity or limited legal capacity Subject is within the exclusion period of another study or is on the "National Volunteer Registry".
References
Publications (0)
Data not yet available